Novo Nordisk licenses Hengrui oral GLP-1/GIP drug HRS-1596
Novo Nordisk will pay $300M upfront for exclusive rights to HRS-1596 outside mainland China, Hong Kong, Macao and Taiwan, in a deal valued up to $2.6B. The phase 1-ready dual GLP-1/GIP agonist targets weight management and type 2 diabetes, with potential once-weekly oral dosing. Additional milestone and sales payments are included, and closing is expected in Q4 2026, subject to U.S. antitrust clearance and customary conditions.
6B. The company will pay $300M upfront for exclusive rights outside mainland China, Hong Kong, Macao and Taiwan. HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist in development for weight management and type 2 diabetes, with potential once-weekly oral dosing. The deal also includes additional milestone and sales-related payments.
S. antitrust clearance and customary conditions.